Apcin manufacturers
- Apcin
-
- $40.00 / 1mg
-
2026-04-09
- CAS:300815-04-7
- Min. Order:
- Purity: 96.74%
- Supply Ability: 10g
|
| Product Name: | Apcin | | Synonyms: | Apcin;3-(2-Methyl-5-nitroimidazol-1-yl)-N-(2,2,2-trichloro-1-phenylaminoethyl)propionamide;Carbamic acid, [2,2,2-trichloro-1-(2-pyrimidinylamino)ethyl]-, 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl ester (9CI);Apcin >=98% (HPLC);2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl 2,2,2-trichloro-1-(pyrimidin-2-ylamino)ethylcarbamate;2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethyl N-{2,2,2-trichloro-1-[(pyrimidin-2-yl)amino]ethyl}carbamate;ligase,pocket,anaphase-promoting,Apcin,recognition,complex,Inhibitor,Cdc20,Anaphase promoting complex,cyclosome,ubiquitylation,inhibit,mitosis,WD40-domain,APC/C,APC;Carbamic acid, N-[2,2,2-trichloro-1-(2-pyrimidinylamino)ethyl]-, 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl ester | | CAS: | 300815-04-7 | | MF: | C13H14Cl3N7O4 | | MW: | 438.65 | | EINECS: | | | Product Categories: | | | Mol File: | 300815-04-7.mol |  |
| | Apcin Chemical Properties |
| density | 1.68±0.1 g/cm3(Predicted) | | storage temp. | room temp | | solubility | DMF: 25 mg/ml; DMSO: 25 mg/ml; DMSO:PBS (pH 7.2) (1:1): 0.5 mg/ml | | pka | 9.67±0.46(Predicted) | | form | powder | | color | white to beige | | InChI | 1S/C13H14Cl3N7O4/c1-8-19-7-9(23(25)26)22(8)5-6-27-12(24)21-10(13(14,15)16)20-11-17-3-2-4-18-11/h2-4,7,10H,5-6H2,1H3,(H,21,24)(H,17,18,20) | | InChIKey | ZEXHXVOGJFGTRX-UHFFFAOYSA-N | | SMILES | CC1=NC=C([N+]([O-])=O)N1CCOC(NC(C(Cl)(Cl)Cl)NC2=NC=CC=N2)=O |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Eye Irrit. 2
Skin Irrit. 2
STOT SE 3 |
| | Apcin Usage And Synthesis |
| Uses | Apcin is a novel inhibitor of the anaphase-promoting complex/cyclosome (APC/C), blocking mitotic exit and being synergistically amplified by co-addition of Ts-Arg-OMe. | | Biochem/physiol Actions | Apcin is an inhibitor of the anaphase-promoting complex/cyclosome (APC/C), a large multimeric complex that functions as a ubiquitin ligase, initiating the metaphase–anaphase transition and regulating ordered transitions through the cell cycle by controlling the ubiquitin-mediated proteolysis of cell cycle proteins. Apcin prevents substrate recognition and inhibits APC/C-dependent ubiquitylation by binding to the D-box binding site of Cdc20, a coactivator required for full activation of APC/C and substrate recognition. The effectiveness of apcin in blocking mitotic exit was synergistically amplified by co-addition of TAME (tosyl-L-arginine methyl ester) or its cell permeable prodrug proTAME, which block Cdc20 binding to the APC/C at a different site than apcin. | | Enzyme inhibitor | This Cdc20 inhibitor (FW = 438.65 g/mol; CAS 300815-04-7; Solubility: 100 mM in DMSO), also named 3-(2-methyl-5-nitroimidazol-1-yl)-N- (2,2,2-trichloro-1-phenylaminoethyl)propionamide, targets substrate interaction of Cell division control protein 20, blocking substrate-mediated Cdc20 loading onto the Anaphase-Promoting Complex. APC is a 13- subunit ubiquitin ligase that initiates the metaphase-anaphase transition and mitotic exit by targeting proteins such as securin and cyclin B1 for ubiquitin-dependent destruction by the proteasome. APC regulates cell cycle progression by forming APC·Cdc20 and APC·Cdh1, two closely related, but functionally distinct, E3 ubiquitin ligase sub-complexes. Cdh1 and Cdc20 have opposing functions in tumorigenesis, with the former largely functioning as a tumor suppressor, and the latter exhibiting an oncogenic function. Because blocking mitotic exit is an effective approach for inducing tumour cell death, the APC/C represents a potential novel target for cancer therapy. APC/C activation during mitosis requires Cdc20binding, forming a co-receptor with the APC/C to recognize substrates containing a destruction box (D-box). APC/C-dependent proteolysis and mitotic exit can be synergistically inhibited by simultaneously disrupting two protein-protein interactions within the APC/C-Cdc20-substrate ternary complex. APC inhibitor, or Apcin, binds to Cdc20, competitively inhibiting ubiquitylation of D-box-containing substrates. Analysis of the crystal structure of the apcin-Cdc20 complex suggests that apcin occupies the D-box-binding pocket on the side face of the WD40-domain. The ability of Apcin to block mitotic exit is enhanced by co-addition of tosyl-l-arginine methyl ester (See TAME), a small molecule that blocks the APC/C-Cdc20 interaction. Apcin also inhibits APC-dependent ubiquitylation and prolongs mitotic duration in RPE1 cells, when administered in combination with proTAME, a prodrug of TAME in vitro (See pro-TAME). | | storage | Store at -20°C |
| | Apcin Preparation Products And Raw materials |
|